Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands

Yuma Nonomiya, Takashi Yokokawa, Kazuyoshi Kawakami, Kazuo Kobayashi, Takeshi Aoyama, Tomomi Takiguchi, Takahito Sugisaki, Kenichi Suzuki, Mitsukuni Suenaga, Takeru Wakatsuki, Kensei Yamaguchi, Yoshikazu Sugimoto, Toshihiro Hama

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand-foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR was 80% (grade 3: 28%) in the Japanese subpopulation in the CORRECT trial; however, more detailed data regarding HFSR in terms of onset and sites of susceptibility are unclear. Additionally, the risk factors for regorafenib-induced severe HFSR are unknown. The aim of this study was to compare HFSR between the hands and feet and identify preexisting risk factors for severe HFSR in Japanese patients receiving regorafenib. We retrospectively examined the onset and severity of HFSR on the hands and feet of patients with metastatic colorectal cancer treated with regorafenib from May 2013 to October 2015 in the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. In addition, we examined the possible association between preexisting clinical factors and severe HFSR. Our results showed that no significant difference in the incidence of HFSR of any grade was observed between the hands (71%) and feet (74%) (p = 0.63). The incidence of grade 3 HFSR was more frequent on the feet (33%) than on the hands (8%) (p < 0.01). The onset of grade 3 HFSR was earlier on the feet than on the hands (p < 0.001). No preexisting risk factor was identified. Our findings indicate that severe HFSR was more prevalent on the feet than on the hands, suggesting the need for appropriate screening for early detection and treatment of regorafenib-induced HSFR.

Original languageEnglish
Pages (from-to)551-556
Number of pages6
JournalOncology research
Volume27
Issue number5
DOIs
Publication statusPublished - 2019 May 7

Fingerprint

Foot
Hand
Skin
regorafenib
Colorectal Neoplasms
Cancer Care Facilities
Incidence
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Nonomiya, Y., Yokokawa, T., Kawakami, K., Kobayashi, K., Aoyama, T., Takiguchi, T., ... Hama, T. (2019). Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands. Oncology research, 27(5), 551-556. https://doi.org/10.3727/096504018X15291727589740

Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands. / Nonomiya, Yuma; Yokokawa, Takashi; Kawakami, Kazuyoshi; Kobayashi, Kazuo; Aoyama, Takeshi; Takiguchi, Tomomi; Sugisaki, Takahito; Suzuki, Kenichi; Suenaga, Mitsukuni; Wakatsuki, Takeru; Yamaguchi, Kensei; Sugimoto, Yoshikazu; Hama, Toshihiro.

In: Oncology research, Vol. 27, No. 5, 07.05.2019, p. 551-556.

Research output: Contribution to journalArticle

Nonomiya, Y, Yokokawa, T, Kawakami, K, Kobayashi, K, Aoyama, T, Takiguchi, T, Sugisaki, T, Suzuki, K, Suenaga, M, Wakatsuki, T, Yamaguchi, K, Sugimoto, Y & Hama, T 2019, 'Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands', Oncology research, vol. 27, no. 5, pp. 551-556. https://doi.org/10.3727/096504018X15291727589740
Nonomiya Y, Yokokawa T, Kawakami K, Kobayashi K, Aoyama T, Takiguchi T et al. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands. Oncology research. 2019 May 7;27(5):551-556. https://doi.org/10.3727/096504018X15291727589740
Nonomiya, Yuma ; Yokokawa, Takashi ; Kawakami, Kazuyoshi ; Kobayashi, Kazuo ; Aoyama, Takeshi ; Takiguchi, Tomomi ; Sugisaki, Takahito ; Suzuki, Kenichi ; Suenaga, Mitsukuni ; Wakatsuki, Takeru ; Yamaguchi, Kensei ; Sugimoto, Yoshikazu ; Hama, Toshihiro. / Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands. In: Oncology research. 2019 ; Vol. 27, No. 5. pp. 551-556.
@article{2739b0bb689f44a08c41bba609adb088,
title = "Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands",
abstract = "Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand-foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR was 80{\%} (grade 3: 28{\%}) in the Japanese subpopulation in the CORRECT trial; however, more detailed data regarding HFSR in terms of onset and sites of susceptibility are unclear. Additionally, the risk factors for regorafenib-induced severe HFSR are unknown. The aim of this study was to compare HFSR between the hands and feet and identify preexisting risk factors for severe HFSR in Japanese patients receiving regorafenib. We retrospectively examined the onset and severity of HFSR on the hands and feet of patients with metastatic colorectal cancer treated with regorafenib from May 2013 to October 2015 in the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. In addition, we examined the possible association between preexisting clinical factors and severe HFSR. Our results showed that no significant difference in the incidence of HFSR of any grade was observed between the hands (71{\%}) and feet (74{\%}) (p = 0.63). The incidence of grade 3 HFSR was more frequent on the feet (33{\%}) than on the hands (8{\%}) (p < 0.01). The onset of grade 3 HFSR was earlier on the feet than on the hands (p < 0.001). No preexisting risk factor was identified. Our findings indicate that severe HFSR was more prevalent on the feet than on the hands, suggesting the need for appropriate screening for early detection and treatment of regorafenib-induced HSFR.",
author = "Yuma Nonomiya and Takashi Yokokawa and Kazuyoshi Kawakami and Kazuo Kobayashi and Takeshi Aoyama and Tomomi Takiguchi and Takahito Sugisaki and Kenichi Suzuki and Mitsukuni Suenaga and Takeru Wakatsuki and Kensei Yamaguchi and Yoshikazu Sugimoto and Toshihiro Hama",
year = "2019",
month = "5",
day = "7",
doi = "10.3727/096504018X15291727589740",
language = "English",
volume = "27",
pages = "551--556",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "5",

}

TY - JOUR

T1 - Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands

AU - Nonomiya, Yuma

AU - Yokokawa, Takashi

AU - Kawakami, Kazuyoshi

AU - Kobayashi, Kazuo

AU - Aoyama, Takeshi

AU - Takiguchi, Tomomi

AU - Sugisaki, Takahito

AU - Suzuki, Kenichi

AU - Suenaga, Mitsukuni

AU - Wakatsuki, Takeru

AU - Yamaguchi, Kensei

AU - Sugimoto, Yoshikazu

AU - Hama, Toshihiro

PY - 2019/5/7

Y1 - 2019/5/7

N2 - Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand-foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR was 80% (grade 3: 28%) in the Japanese subpopulation in the CORRECT trial; however, more detailed data regarding HFSR in terms of onset and sites of susceptibility are unclear. Additionally, the risk factors for regorafenib-induced severe HFSR are unknown. The aim of this study was to compare HFSR between the hands and feet and identify preexisting risk factors for severe HFSR in Japanese patients receiving regorafenib. We retrospectively examined the onset and severity of HFSR on the hands and feet of patients with metastatic colorectal cancer treated with regorafenib from May 2013 to October 2015 in the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. In addition, we examined the possible association between preexisting clinical factors and severe HFSR. Our results showed that no significant difference in the incidence of HFSR of any grade was observed between the hands (71%) and feet (74%) (p = 0.63). The incidence of grade 3 HFSR was more frequent on the feet (33%) than on the hands (8%) (p < 0.01). The onset of grade 3 HFSR was earlier on the feet than on the hands (p < 0.001). No preexisting risk factor was identified. Our findings indicate that severe HFSR was more prevalent on the feet than on the hands, suggesting the need for appropriate screening for early detection and treatment of regorafenib-induced HSFR.

AB - Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand-foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR was 80% (grade 3: 28%) in the Japanese subpopulation in the CORRECT trial; however, more detailed data regarding HFSR in terms of onset and sites of susceptibility are unclear. Additionally, the risk factors for regorafenib-induced severe HFSR are unknown. The aim of this study was to compare HFSR between the hands and feet and identify preexisting risk factors for severe HFSR in Japanese patients receiving regorafenib. We retrospectively examined the onset and severity of HFSR on the hands and feet of patients with metastatic colorectal cancer treated with regorafenib from May 2013 to October 2015 in the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. In addition, we examined the possible association between preexisting clinical factors and severe HFSR. Our results showed that no significant difference in the incidence of HFSR of any grade was observed between the hands (71%) and feet (74%) (p = 0.63). The incidence of grade 3 HFSR was more frequent on the feet (33%) than on the hands (8%) (p < 0.01). The onset of grade 3 HFSR was earlier on the feet than on the hands (p < 0.001). No preexisting risk factor was identified. Our findings indicate that severe HFSR was more prevalent on the feet than on the hands, suggesting the need for appropriate screening for early detection and treatment of regorafenib-induced HSFR.

UR - http://www.scopus.com/inward/record.url?scp=85064285861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064285861&partnerID=8YFLogxK

U2 - 10.3727/096504018X15291727589740

DO - 10.3727/096504018X15291727589740

M3 - Article

VL - 27

SP - 551

EP - 556

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 5

ER -